PPH Lawyer

Redux

Redux, or dexfenfluramine, is another diet drug that has been linked to primary pulmonary hypertension (PPH). It is an updated version of fenfluramine (the fen in fen-phen) and was actually approved by the FDA. It was pulled from the market in 1997 at the same time as Fen-Phen due to concerns over heart damage, among other things.

Redux is an appetite suppressant that works by convincing the body to increase the amount of serotonin in the body. Serotonin is one of the chemicals released by the body. In addition to its use for making people happy, serotonin also contributes to a feeling of fullness and contentedness. Because of this, the increased levels of serotonin in the body reduce both appetite and carbohydrate cravings. Redux was particularly effective in people who were 20 to 30% overweight. Changes were seen in the first four weeks of use.

Unlike amphetamines, which are another class of weight-loss drugs, Redux was not shown to be addictive and was thought to be ok over a long period of time. Unfortunately, Redux was shown to have a tie to Primary Pulmonary Hypertension in a similar way as Fen-Phen. In addition to causing PPH, these drugs have been shown to cause heart valve damage and contribute to many mental problems such as a lack of short-term memory as well.

If you or someone you know has taken Redux and then been diagnosed with Primary Pulmonary Hypertension (PPH), contact that the PPH Lawsuit Attorneys of Williams Kherkher at 1-800-220-9341 to discuss your case and to schedule an initial consultation.